A House lawmaker is investigating whether the three largest pharmacy benefit managers (PBMs) targeted independent pharmacies with retaliatory audits, according to STAT. The inquiry focuses on whether these audits were used as a punitive measure against smaller pharmacy operators.
This investigation matters for healthcare and pharmaceutical leaders because PBMs play a central role in drug pricing and pharmacy reimbursement. Increased scrutiny may lead to regulatory changes or shifts in audit practices, affecting relationships with independent pharmacies and supply chain management.
